Trueline Therapeutics Inc.

proven paths - new directions

pursuing validated targets

with innovative approaches

Trueline Therapeutics Inc.

Getting a cancer diagnosis remains to be a life-changing and emotionally devastating experience. We are unified in the mission to improve the treatment landscape for cancer patients by pursuing validated targets with novel approaches tailored to the patient's need.

Pipeline

Target/ Modality

Route

Cancer Indication

Lead Optimization

IND Enabling

Phase 1

TTX-810

TTX-564

TTX-114

MCL1 Inhibitor

CD3/CD33 Bispecific

HCK/BTK Inhibitor

i.v.

s.c.

oral

Solid Cancer

Hematological Cancer

Myelodysplastic Syndrome

Solid Cancer

Hematological Cancer

MCL1 inhibitor

TTX-810


MCL-1 acts as a "brake" on the apoptosis pathway which normally clears unwanted cells like cancer. Inhibition of MCL-1 rapidly induces cancer cell death.

CD3/CD33 Bispecific

TTX-564


Directing T-cells to target clustered CD33 provides a safe approach to restore the anti-tumor response of the immune system.

HCK/BTK inhibitor

TTX-114


Blocking HCK/BTK with one shot targets the Achilles' heel for leukemia and lymphoma cell survival.

For partnerships, investment opportunities, or to learn more about our work, contact us.